EVAXION BIOTECH A/S (EVAX)

Which stocks are moving after the closing bell on Thursday?

These stocks are moving in today's after hours session

Evaxion announces positive preclinical data for cytomegalovirus (CMV) vaccine program EVX-V1

New preclinical data demonstrates that CMV antigens identified with Evaxion’s AI-Immunology™ platform trigger targeted immune responses Results also...

Evaxion announces business update and third quarter 2024 financial results

Evaxion announces business update and third quarter 2024 financial results

COPENHAGEN, Denmark, October 31, 2024 - Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing...

Evaxion to announce business update and third quarter 2024 financial results on October 31

COPENHAGEN, Denmark, October 28, 2024 - Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing...

Strong validation of Evaxion’s AI-Immunology™ platform in multiple clinical trials

Data from three separate clinical trials documents the strong ability of the AI-Immunology™ platform to select clinically relevant vaccine targets...

Recent clinical data confirms significantly improved predictive power of Evaxion's AI-Immunology™ platform

Improved precision of the AI-Immunology™ platform in predicting clinically relevant vaccine targets boosts the potential of its AI-derived vaccine...

Evaxion significantly expands vaccine development collaboration with MSD

Agreement provides MSD with options to license Evaxion’s preclinical, AI-designed vaccine candidates EVX-B2 and EVX-B3Evaxion will host a conference call...

Life Sciences Virtual Investor Forum Presentations Now Available for Online Viewing

Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com

Evaxion launches improved AI-Immunology™ platform for vaccine antigen prediction

The new version 5.0 of the AI model EDEN™ features a novel toxin antigen predictor, is trained on an expanded dataset and includes an advanced protein...

Life Sciences Virtual Investor Forum Agenda Announced for September 19th

Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com

Evaxion reports convincing one-year data from phase 2 trial on AI-designed personalized cancer vaccine EVX-01

11 out of 16 patients had objective clinical responses, equaling a 69% Overall Response Rate15 out of the 16 patients had a reduction of their tumors...

Evaxion obtains pre-clinical Proof-of-Concept for mRNA Gonorrhea vaccine candidate EVX-B2

New pre-clinical data demonstrates that the novel EVX-B2 mRNA vaccine candidate triggers a targeted immune response The specific immune response leads to...

EVAX Stock Earnings: Evaxion Biotech Beats EPS, Beats Revenue for Q2 2024

EVAX stock results show that Evaxion Biotech beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.

EVAX Stock Earnings: Evaxion Biotech Beats EPS, Beats Revenue for Q2 2024

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Evaxion Biotech (NASDAQ:EVAX) just reported results for the second quarter of 2...

Evaxion Announces Business Update and Second Quarter 2024 Financial Results

Evaxion to Announce Business Update and Second Quarter 2024 Financial Results on August 14

COPENHAGEN, Denmark, Aug. 12, 2024 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage TechBio company...

Evaxion to Present One-Year Clinical Efficacy Data from its Phase 2 Study on Lead Cancer Vaccine Candidate, EVX-01, at the ESMO Congress 2024 in September

COPENHAGEN, Denmark, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in...

Evaxion Showcases Improved Performance of Key Building Block in AI-Immunology™ at Computational Biology Conference

Central AI-Immunology™ Building Block: Evaxion’s proprietary in-house developed building block, EvaxMHC, is used across the AI-Immunology™ platform...

Evaxion Reinforces Milestone Timeline and Provides Shareholder Update

COPENHAGEN, Denmark, July 03, 2024 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage TechBio company...

Evaxion Receives Positive Feedback on Patent Application for AI-Based Novel Cancer Vaccine Target Identification Method

Positive Feedback Received: An International Preliminary Report on Patentability (IPRP) indicates promising prospects for obtaining granted patents and...

iAccess Alpha's Buyside Best Ideas Virtual Summer Conference June 25-26, 2024

Evaxion Publishes Data, Showing 67% Objective Response Rate in Metastatic Melanoma for the AI-Designed Personalized Cancer Vaccine EVX-01, in Leading Medical Journal

A 67% objective response rate (ORR) is reported in the publication summarizing results from the Phase 1 study assessing Evaxion’s personalized cancer...

Evaxion Presents Positive and Validating Immune Data from Ongoing Phase 2 Trial with AI-Designed EVX-01 Vaccine at the ASCO Annual Meeting 2024

Evaxion’s AI-designed cancer vaccine, EVX-01, triggered a specific and tumor-targeting immune response in all assayed melanoma patientsFindings further...

EVAX Stock Earnings: Evaxion Biotech Beats EPS, Beats Revenue for Q1 2024

EVAX stock results show that Evaxion Biotech beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.

Evaxion Announces Business Update and First Quarter 2024 Financial Results

Evaxion Announces Business Update and First Quarter 2024 Financial Results

COPENHAGEN, Denmark, May 28, 2024 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (

Evaxion to Present New Positive Data from Ongoing Phase 2 Study on Lead Vaccine Candidate EVX-01 at the American Society of Clinical Oncology Annual Meeting 2024

EVX-01 induced positive clinically relevant immune responses in all assessed patientsBooster immunizations tended to increase the immune responseThe...

Evaxion Receives Nasdaq Notification

COPENHAGEN, Denmark, May 10, 2024 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage TechBio company...

Evaxion et un collaborateur anonyme annoncent des résultats encourageants concernant les antigènes du vaccin EVX-B1 contre l'infection à staphylocoque doré

Evaxion et son collaborateur ont testé les antigènes du vaccin conçus par Evaxion contre le staphylocoque doré sur un modèle animal cliniquement pertinent...

Evaxion und nicht offengelegter Kooperationspartner veröffentlichen vielversprechende Ergebnisse für EVX-B1-Impfstoff-Antigene gegen Staphylococcus aureus-Infektionen

Evaxion und sein Kooperationspartner testeten die von Evaxion entwickelten Impfstoff-Antigene gegen Staphylococcus aureus in einem klinisch relevanten...